Fifty-four homologue (ffh) from streptococcus pneumoniae

ABSTRACT

The invention provides ffh polypeptides and DNA (RNA) encoding ffh polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ffh polypeptides to screen for antibacterial compounds.

This application is a divisional of U.S. application No. 08/923,772,filed Sep. 2, 1997, now U.S. Pat. No. 5,972,651.

FIELD OF THE INVENTION

This invention relates to newly identified polynucleotides andpolypeptides, and their production and uses, as well as their variants,agonists and antagonists, and their uses, In particular, in these and inother regards, the invention relates to polynucleotides and polypeptidesof the ffh (Fifty-Four Homologue) family, hereinafter referred to as“ffh”.

BACKGROUND OF THE INVENTION

The Streptococci make up a medically important genera of microbes knownto cause several types of disease in humans, including, for example,otitis media, conjunctivitis, pneumonia, bacteremia, meningitis,sinusitis, pleural empyema and most particularly meningitis, such as forexample infection of cerebrospinal fluid. Since its isolation more than100 years ago, Streptococcus pneumoniae has been one of the moreintensively studied microbes. For example, much of our earlyunderstanding that DNA is, in fact, the genetic material was predicatedan the work of Griffith and of Avery, Macleod and McCarty using thismicrobe. Despite the vast amount of research with S. pneumoniae, manyquestions Concerning the virulence of this microbe remain, It isparticularly preferred to employ Streptococcal genes and gene productsas targets for the development of antibiotics

The frequency of Streptococcus pneumoniae infections has risendramatically in the past 20 years. This has been attributed to theemergence of multiply antibiotic resistant strains and an increasingpopulation of people with weakened immune systems. It is no longeruncommon to isolate Streptococcus pneumoniae strains which are resistantto some or all of the standard antibiotics. This has created a demandfor both new antimicrobial agents and diagnostic tests for thisorganism.

Ffh, and homologues, are components of the protein secretary apparatusof bacteria and play an essential role in targeting of proteins to thecytoplasmic membrane (and possibly beyond). Ffh is the bacterialhomologue of the 54 kDa sub-unit of the eukaryotic Signal RecognitionParticle. Inhibition of function of the protein is injurious tobacterial cells.

Clearly, there is a need for factors such as the compounds of theinvention, that have a present benefit of being useful to screencompounds for antibiotic activity. Such factors are also useful todetermine their role in pathogenesis of infection, dysfunction anddisease. There is also a need for identification and characterization ofsuch factors and their antagonists and agonists which can play a role inpreventing ameliorating or correcting infections dysfunctions ordiseases.

The polypeptides of the invention have amino acid sequence homology to aknown ffh protein encoded by Streptococcus mutans (nucleotides 969 to2519 of Genbank Entry Accession number U88582).

SUMMARY OF THE INVENTION

It is an object of the invention to provide polypeptides that have beenidentified as ffh polypeptides of the invention by homology between theamino acid sequence set out in Table 1 [SEQ ID NO: 2] and a known aminoacid sequence or sequences of other proteins such as ffh protein,encoded by Streptococcus mutans.

It is a further object of the invention to provide polynucleotides thatencode ffh polypeptides, particularly polynucleotides that encode thepolypeptide herein designated ffh.

In a particularly preferred embodiment of the invention thepolynucleotide comprises a region encoding ffh polypeptides comprisingthe sequence set out in Table 1 [SEQ ID NO:1], or a variant thereof.

In another particularly preferred embodiment of the invention there is affh protein from Streptococcus pneumoniae comprising the amino, acidsequence of Table 1 [SEQ ID NO:2], or a variant thereof.

In accordance with another aspect of the invention there is provided anisolated nucleic acid molecule encoding a mature polypeptide expressibleby the Streptococcus pneumoniae 0100993 strain contained in thedeposited strain.

In further aspect of the invention there are provided isolated nucleicacid molecules encoding ffh, particularly Streptococcus pneumoniae ffh,including mRNAs, cDNAs, genomic DNAs, Further embodiments of theinvention include biologically, diagnostically, prophylactically,clinically or therapeutically useful variants thereof, and compositionscomprising the same.

In accordance with another aspect of the invention, there is providedthe use of a polynucleotide of the invention for therapeutic orprophylactic purposes, in particular genetic immunization. Among theparticularly preferred embodiments of the invention are naturallyoccurring allelic variants of ffh and polypeptides encoded thereby.

Another aspect of the invention there at provided polypeptides ofStreptococcus pneumoniae referred to herein as ffh as well asbiologically, diagnostically, prophylactically, clinically ortherapeutically useful variants thereof, and compositions comprising thesame.

Among the particularly preferred embodiments of the invention arevariants of ffh polypeptide encoded by naturally occurring alleles ofthe ffh gene.

In a preferred embodiment of the invention there are provided methodsfor producing the aforementioned ffh polypeptides.

In accordance with yet another aspect of the invention, there areprovided inhibitors to such polypeptides, useful as antibacterialagents, including, for example, antibodies.

In accordance with certain preferred embodiments of the invention thereare provided products, compositions and methods for assessing ffhexpression, treating disease, for example, otitis media, conjunctivitis,pneumonia, bacteremia, meningitis, sinusitis, pleural empyema adendocarditis, and most particularly meningitis, such as for exampleinfection of cerebrospinal fluid, assaying genetic variation andadministering a ffh polypeptide or polynucleotide to an organism toraise an immunological response against a bacteria, especiallyStreptococcus pneumoniae bacteria.

In accordance with certain preferred embodiments of this and otheraspects of to invention there are provided polynucleotides thathybridize to ffh polynucleotide sequences, particularly under stringentconditions.

In certain preferred embodiments of the invention there are providedantibodies against ffh polypeptides.

In other embodiments of the invention there are provided methods foridentifying compounds which bind to or otherwise interact with andinhibit or activate an activity of a polypeptide or polynucleotide ofthe invention comprising: contacting a polypeptide or polynucleotide ofthe invention with a compound to be screened under conditions to permitbinding to or other interaction between the compound and the polypeptideor polynucleotide to assess the binding to or other interaction with thecompound such binding or interaction being associated with a secondcomponent capable of providing a detectable signal in response to thebinding or interaction of the polypeptide or polynucleotide with thecompound; and determining whether the compound binds to or otherwiseinteracts with and activates or inhibits an activity of the polypeptideor polynucleotide by detecting the presence or absence of a signalgenerated from the binding or interaction of he compound with thepolypeptide or polynucleotide.

In accordance with yet another aspect of the invention, there areprovided ffh agonists and antagonists, preferably bacteriostatic orbacteriocidal agonist and antagonists.

In a further aspect of the invention there are provided compositionscomprising a ffh polypeptide or a ffh polypeptide for administration toa cell or to a multicellular organism.

Various changes and modifications within the spirit and scope of thedisclosed invention will become readily apparent to those skilled in theart from reading the following descriptions and from reading the otherparts of the present disclosure.

GLOSSARY

The following definitions are provided to facilitate understanding ofcertain terms used frequently herein.

“Host cell” is a cell which has been transformed or transfected, or iscapable of transformation or transfection by an exogenous polynucleotidesequence.

“Identity,” as known in the art; is relationship a between two or morepolypeptide sequences or two or more polynucleotide sequences, asdetermined by comparing the sequences. In the art “identity” also meansthe degree of sequence relatedness between polypeptide or polynucleotidesequences, as be case may be, as determined by the match between stringsof such sequences. “Identity” and “similarity” can be readily calculatedby known methods, including but not limited to those described in(Computational Molecular Biology, Lesk, A. M., ed., Oxford UniversityPress, New York, 1988; Biocomputing: Informatics and Genome Projects,Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis ofSequence Data, Part 1, Griffin, A. M., and Griffin, H. G., eds., HumanaPress, New Jersey, 1994; Sequence Analysis in Molecular Biology, vonHeinje, G., Academic Press, 1987; and Sequence Analysis Primer,Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991;and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073 (1988).Preferred methods to determine identity are designed to give the largestmatch between the sequences tested. Methods to determine identity andsimilarity are codified in publicly available computer program.Preferred computer program methods to determine identity and similaritybetween two sequences include, but are not limited to, the GCG programpackage (Devereux, J., et al., Nucleic Acids Research 12(l): 387(1984)), BLASTP, BLASTN, and FASTA (Atschul, S. F. er. al., J. Molec.Biol. 215: 403-410 (1990). The BLAST X program is publicly availablefrom NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBINLM NIH Bethesda, Md. 20894; Altschul, S., et al., J. Mol. Biol. 215:403-410 (1990). As an illustration by a polynucleotide having anucleotide sequence having at least, for example, 95%) “identity” to areference nucleotide sequence of SEQ ID NO: 1 it is intended that thenucleotide sequence of the polynucleotide is identical to the referencesequence except that the polynucleotide sequence may include up to fivepoint mutations per each 100 nucleotides of the reference nucleotidesequence of SEQ ID NO: 1. In other words, to obtain a polynucleotidehaving a nucleotide sequence at least 95% identical to a referencenucleotide sequence, up to 5% of the nucleotides in the referencesequence may be deleted or substituted with another nucleotide, or anumber of nucleotides up to 5% of the total nucleotides in the referencesequence may be inserted into the reference sequence. These mutations ofthe reference sequence may occur at the 5 or 3 terminal positions of thereference nucleotide sequence or anywhere between those terminalpositions, interspersed either individually among nucleotides in thereference sequence or in one or more contiguous groups within thereference sequence. Analogously, by a polypeptide having an amino acidsequence having at least for example, 95% identity to a reference aminoacid sequence of SEQ ID NO:2 is intended that the amino acid sequence ofthe polypeptide is identical to the reference sequence except that thepolypeptide sequence may include up to five amino acid alterations pereach 100 amino acids of the reference amino acid of SEQ ID NO: 2. Inother words, to obtain a polypeptide having an amino acid sequence atleast 95% identical to a reference amino acid sequence, up to 5% of theamino acid residues in the reference sequence may be deleted orsubstituted with another amino acid, or a number of amino acids up to 5%of the total amino acid residues in the reference sequence may beinserted into the reference sequence. These alterations of the referencesequence may occur at the amino or carboxy terminal positions of thereference amino acid sequence or anywhere between those terminalpositions, interspersed either individually among residues in thereference sequence or in one or more contiguous groups within thereference sequence.

“Isolated” altered “by the hand of man” from its natural state i.e., ifit occurs in nature, it has been charged or removed from its originalenvironment, or both. For example, a polynucleotide or a polypeptidenaturally present in a living organism is not “isolated,” but the samepolynucleotide or polypeptide separated from ie coexisting materials ofits natural state is “isolated”, as the term is employed herein.

“Polynucleotide(s)” generally refers to any polyribonucleotide orpolydeoxribonucleotide, which may be unmodified RNA or DNA or modifiedRNA or DNA. “Polynucleotide(s)” include, without limitation, single- anddouble-stranded DNA, DNA that is a mixture of single- anddouble-stranded regions or single-, double- and triple-stranded regions,single- and double-stranded RNA, and RNA that is mixture of single- anddouble-stranded regions, hybrid molecules comprising DNA and RNA thatmay be single-stranded or, more typically, double-stranded, ortriple-stranded regions, or a mixture of single- and double-strandedregions. In addition, “polynucleotide” as used herein refers totriple-stranded regions comprising RNA or DNA or both RNA and DNA. Thestands in such regions may be from the same molecule or from differentmolecules. The regions may include all of one or more of the molecules,but more typically involve only a region of some of the molecules. Oneof the molecules of a triple-helical region often is an oligonucleotide.As used herein, the term, “polynucleotides(s)” also includes DNAs orRNAs as described above that contain one or more modified bases. Thus,DNAs or RNAs with backbones modified for stability or for other reasonsare “polynucleotide(s)” as that term is intended herein. Mover, DNAs orRNAs comprising unusual bases, such as inosine, or modified bases, suchas tritylated bases, to name just two examples, are polynucleotides; asthe term is used herein. It will be appreciated that a great variety ofmodifications have been made to DNA and RNA that serve many usefulpurposes known to those of skill in the art. The term“polynucleotide(s)” as it is employed herein embraces such chemically,enzymatically or metabolically modified forms of polynucleotides, aswell as the chemical forms of DNA and RNA characteristic of viruses andcells, including, for example, simple and complex cells.

“Polynucleotide(s)” also embraces short polynucleotides often referredto as oligonucleotide(s).

“Polypeptide(s)” refers to any peptide or protein comprising two or moreamino acids joined to each other by peptide bonds or modified peptidebonds. “Polypeptide(s)” refers to both short chains, commonly referredto as peptic, oligopeptides and oligomers and to longer chains generallyreferred to as proteins. Polypeptides may contain amino acids other thanthe 20 gene encoded amino acids. “Polypeptide(s)” include those modifiedeither by natural processes, such as processing and otherpost-translation modifications, but also by chemical modificationtechniques. Such modifications are well described in basic texts and inmore detailed monographs, as well as in a voluminous researchliterature, and they are well known to those of skill in the art. Itwill to appreciated that the same type of modification nay be present inthe same or varying degree at several sites in a given polypeptide.Also, a given polypeptide may contain many types of modifications.Modifications can occur anywhere in a polypeptide, including the peptidebackbone, the amino acid side-chains and the amino or carboxyl termini.Modifications include, for example, acetylation, acylation,ADP-ribosylation, amidation, covalent attachment of flavin, covalentattachment of a heme moiety, covalent attachment of a nucleotide ornucleotide derivative, covalent attachment of a lipid or lipidderivative, covalent attachment of phosphotidylinositol, cross-linking,cyclization, disulfide bond formation, demethylation, formation ofcovalent cross-links formation of cysteine, formation of pyroglutamate,formylation, gamma-carboxylation, glycosylation, GPI anchor formationiodination, methylation, myristoylation, oxidation, proteolyticprocessing, phosphorylation, prenylation, racemization, glycosylation,lipid attachment sulfation, gamma-carboxylation of glutamic acidresidues, hydroxylation and ADP-ribosylation, selenoylation, sulfation,transfer-RNA mediated addition of amino acids to proteins such asarginylation, and ubiquitination. See, for instance, PROTEINS-STRUCTUREAND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman andCompany, New York (1993) and Wold F., Posttranslational ProteinModifications Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONALCOVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press,New York (1983); Seifter et al., Meth. Enzymol. 182:626-646 (1990) andRattan et al., Protein Synthesis: Posttranslational Modifications andAging, Ann. N.Y. Acad. Sci. 663: 48-62 (1992). Polypeptides may bebranched or cyclic, with or without branching, Cyclic, branched andbranched circular polypeptides may result from post-translationalnatural processes and may be made by entirely synthetic methods, aswell.

“Variant(s)” as the term is used herein, is a polynucleotide orpolypeptide that differs from a reference polynucleotide or polypeptiderespectively, but retains essential properties. A typical variant of apolynucleotide differs in nucleotide sequence from another, referencepolynucleotide. Changes in the nucleotide sequence, of the variant mayor may not alter the amino acid sequence of a polypeptide encoded by thereference polynucleotide. Nucleotide changes may result in amino acidsubstitutions, additions, deletions, fusions and truncations in thepolypeptide encoded by the reference sequence, as discussed below. Atypical variant of a polypeptide differs in amino acid sequence fromanother, reference polypeptide. Generally, differences are limited sothat the sequences of the reference polypeptide and the variant areclosely similar overall and, in many regions, identical. A variant andreference polypeptide may differ in amino acid sequence by one or moresubstitutions, additions, deletions in any combination. A substituted orinserted amino acid residue may or may not be one encoded by the geneticcode. A variant of a polynucleotide or polypeptide may be a naturallyoccurring such as an allelic variant, or it may be a variant that is notknown to occur naturally. Non-naturally occurring variants ofpolynucleotides and polypeptides may be node by mutagenesis techniques,by direct synthesis, and by other recombinant methods known to skilledartisans.

DESCRIPTION OF THE INVENTION

The invention relates to ffh polypeptides and polynucleotides asdescribed in greater detail below. In particular the invention relatesto polypeptides and polynucleotides of a ffh of Streptococcuspneumoniae, which is related by amino acid sequence homology to ffhpolypeptide, encoded by Streptococcus mutans. The invention relatesespecially to ffh having the nucleotide and amino acid sequences set outin Table 1 [SEQ ID NO: 1] and Table 1 [SEQ ID NO: 2] respectively, andto the ffh nucleotide sequences of the DNA in the deposited strain andamino acid sequences encoded thereby.

TABLE 1 ffh Polynucleotide and Polypeptide Sequences (A) Sequences fromStreptococcus pneumoniaeffh polynucleotide sequence [SEQ ID NO:1]. 5′-ATGGCATTTGAAAGTTTAACAGAACGTTTGCAGAACGTCTTTAAAAATCTACGTAAAAAAGGAAAAATCTCTGAATCTGATGTCCAAGAGGCAACCAAAGAAATTCGCTTGGCCTTGCTCGAGGCCGACGTTGCCTTGCCTGTTGTAAAGGACTTTATCAAGAAAGTTCGTGAGCGTGCAGTCGGGCATGAGGTCATTGATACACTTAATCCTGCGCAACAGATTATTAAAATCGTTGATGAGGAACTGACAGCCGTTTTAGGTTCTGATACGGCAGAAATTATCAAGTCACCTAAGATTCCAACCATCATCATGATGGTTGGTTTACAAGGGGCTGGTAAAACAACCTTTGCTGGTAAATTGGCCAACAAACTCAAGAAAGAAGAAAATGCTCGTCCTTTGATGATTGCGGCGGATATTTATCGTCCAGCTGCCATTGACCAGCTTAAGACCTTGGGACAACAGATTGATGTGCCTGTCTTTGCACTTGGAACAGAAGTACCAGCTGTTGAGATTGTACGTCAAGGTTTGGAGCAAGCCCAAACTAATCATAACGACTATGTCTTGATTGATACTGCGGGTCGTTTGCAGATTGATGAGCTCCTCATGAATGAGCTTCGTGATGTGAAAGTATTGGCTCAACCAAATGAAATCTTGCTTGTCGTTGATGCTATGATTGGTCAGGAAGCAGCCAATGTTGCGCGTGAGTTTAATGCTCAGTTGGAAGTGACTGGGGTCATCCTTACCAAGATTGATGGTGATACTCGTGGTGGTGCTGCTCTGTCTGTTCGTCACATCACTGGAAAACCAATCAAGTTCACTGGTACAGGTGAAAAAATTACAGATATCGAAACCTTCCACCCAGACCGTATGTCTAGCCGTATCCTTGGCATGGGGGATATGCTCACTTTGATTGAGAAAGCTTCTCAGGAATACGATGAACAAAAAGCCCTTGAAATGGCTGAGAAGATGCGCGAAAACACCTTTGATTTTAATGATTTCATCGATCAATTAGATCAGGTGCAAAATATGGGGCCGATGGAAGACTTGCTCAAGATGATTCCAGGTATGGCCAACAATCCAGCACTTCAAAACATGAAGGTGGATGAACGCCAGATTGCTCGTAAACGTGCCATTGTGTCTTCGATGAdATCTGAAGAACGTGAAAACCCAGATTTGTTAAATCCAAGCCGTCGCCGTCGTATTGCTGCTGGTTCTGGAAATACATTCGTCGAAGTCAATAAATTCATCAAGGACTTTAACCAGGCTAAACAGCTCATGCAGGGTGTTATGTCTGGGGATATGAATAAAATGATGAAGCAAATGGGGATTAATCCAAATAACCTTCCTAAAAATATGCCAAATATGGGAGGAATGGATATGTCTGCCCTTGAAGGAATGATGGGACAAGGCGGTATGCCTGACTTATCAGCTCTCGGAGGAGCAGGAATGCCAGATATGAGCCAGATGTTTGGTGGCGGTTTGAAAGGTAAAATTGGTGAATTTGCCATGAAACAGTCCATGAAACGTATGGCTAACAAAATGAAGAAAGCGAAGAAGAAACGCAAG-3′                                 1569(B) ffh polypeptide sequence deduced from the polynucleotide sequence inthis table [SEQ ID NO:2]. NH₂-MAFESLTERLQNVFKNLRKKGKISESDVQEATKEIRLALLEADVALPVVKDFIKKVRERAVGHEVIDTLNPAQQIIKIVDEELTAVLGSDTAEIIKSPKIPTIIMMVGLQGAGKTTFAGKLANKLKKEENARPLMIAADIYRPAAIDQLKTLGQQIDVPVFALGTEVPAVEIVRQGLEQAQTNHNDYVLIDTAGRLQIDELLMNELRDVKVLAQPHEILLVVDAMIGQEAANVAREFNAQLEVIGVILTKIDGDTRGGAALSVRHITGKPIKFTGTGEKITDIETFHPDRMSSRILGMGDMLTLIEKASQEYDEQKALEMAEKMRENTFDFNDFIDQLDQVQNMGPMEDLLKMIPGMANNPALQNMKVDERQIARKRAIVSSMTSEERENPDLLNPSRRRRIAAGSGNTFVEVNKFIKDFNQAKQLMQGVMSGDMNKMMKQMGINPNNLPKNMPNMGGMDMSALEGMMGQGGMPDLSALGGAGMPDMSQMFGGGLKGKIGEFAMKQSMKRMANKMKKAKKKRK-COOH (C) Polynucleotide sequenceembodiments [SEQ ID NO:1]. X-(R₁)_(n)-ATGGCATTTGAAAGTTTAACAGAACGTTTGCAGAACGTCTTTAAAAATCTACGTAAAAAAGGAAAAATCTCTGAATCTGATGTCCAAGAGGCAACCAAAGAAATTCGCTTGGCCTTGCTCGAGGCCGACGTTGCCTTGCCTGTTGTAAAGGACTTTATCAAGAAAGTTCGTGAGCGTGCAGTCGGGCATGAGGTCATTGATACACTTAATCCTGCGCAACAGATTATTAAAATCGTTGATGAGGAACTGACAGCCGTTTTAGGTTCTGATACGGCAGAAATTATCAAGTCACCTAAGATTCCAACCATCATCATGATGGTTGGTTTACAAGGGGCTGGTAAAACAACCTTTGCTGGTAAATTGGCCAACAAACTCAAGAAAGAAGAAAATGCTCGTCCTTTGATGATTGCGGCGGATATTTATCGTCCAGCTGCCATTGACCAGCTTAAGACCTTGGGACAACAGATTGATGTGCCTGTCTTTGCACTTGGAACAGAAGTACCAGCTGTTGAGATTGTACGTCAAGGTTTGGAGCAAGCCCAAACTAATCATAACGACTATGTCTTGATTGATACTGCGGGTCGTTTGCAGATTGATGAGCTCCTCATGAATGAGCTTCGTGATGTGAAAGTATTGGCTCAACCAAATGAAATCTTGCTTGTCGTTGATGCTATGATTGGTCAGGAAGCAGCCAATGTTGCGCGTGAGTTTAATGCTCAGTTGGAAGTGACTGGGGTCATCCTTACCAAGATTGATGGTGATACTCGTGGTGGTGCTGCTCTGTCTGTTCGTCACATCACTGGAAAACCAATCAAGTTCACTGGTACAGGTGAAAAAATTACAGATATCGAAACCTTCCACCCAGACCGTATGTCTAGCCGTATCCTTGGCATGGGGGATATGCTCACTTTGATTGAGAAAGCTTCTCAGGAATACGATGAACAAAAAGCCCTTGAAATGGCTGAGAAGATGCGCGAAAACACCTTTGATTTTAATGATTTCATCGATCAATTAGATCAGGTGCAAAATATGGGGCCGATGGAAGACTTGCTCAAGATGATTCCAGGTATGGCCAACAATCCAGCACTTCAAAACATGAAGGTGGATGAACGCCAGATTGCTCGTAAACGTGCCATTGTGTCTTCGATGACATCTGAAGAACGTGAAAACCCAGATTTGTTAAATCCAAGCCGTCGCCGTCGTATTGCTGCTGGTTCTGGAAATACATTCGTCGAAGTCAATAAATTCATCAAGGACTTTAACCAGGCTAAACAGCTCATGCAGGGTGTTATGTCTGGGGATATGAATAAAATGATGAAGCAAATGGGGATTAATCCAAATAACCTTCCTAAAAATATGCCAAATATGGGAGGAATGGATATGTCTGCCCTTGAAGGAATGATGGGACAAGGCGGTATGCCTGACTTATCAGCTCTCGGAGGAGCAGGAATGCCAGATATGAGCCAGATGTTTGGTGGCGGTTTGAAAGGTAAAATTGGTGAATTTGCCATGAAACAGTCCATGAAACGTATGGCTAACAAAATGAAGAAAGCGAAGAAGAAACGCAAG-(R₂)_(n)-Y (D) Polypeptide sequenceembodiments [SEQ ID NO:2]. X-(R₁)_(n)-MAFESLTERLQNVFKNLRKKGKISESDVQEATKEIRLALLEADVALPWKDFIKKVRERAVGHEVIDTLN.PAQQIIKIVDEELTAVLGSDTAEIIKSFKIPTIIMMVGLQGAGKTTFAGKLANKLKKEENARPLMIAADIYRPAAIDQLKTLGQQIDVPVFALGTEVPAVEIVRQGLEQAQTNHNDYVLIDTAGRLQIDELLMNELRDVKVLAQPNEILLVVDAMIGQEAANVAREFNAQLEVTGVILTKIDGDTRGGAALSVRHITGKPIKFTGTGEKITDIETFHPDRMSSRILGMGDMLTLIEKASQEYDEQKALEMAEKMRENTFDFNDFIDQLDQVQNMGPMEDLLKMIPGMANNPALQNMKVDERQIARKRAIVSSMTSEERENPDLLNPSRRRRIAAGSGNTFVEVNKFIKDFNQAKQLMQGVMSGDMNKMMKQMGINPNNLPKNMPNMGGMDMSALEGMMGQGGMPDLSALGGAGMPDMSQMFGGGLKGKIGEFAMKQSMKRMANKMKKAKKKRK-(R₂)_(n)-Y

Deposited Materials

A deposit containing a Streptococcus pneumoniae 0100993 strain has beendeposited with the National Collections of Industrial and MarineBacteria Ltd. (herein “NCIMB”), 23 St. Machar Drive, Aberdeen AB2 1RY,Scotland on Apr. 11, 1996 and assigned deposit number 40794. The depositwas described as Streptococcus peumnoniae 0100993 on deposit. On Apr.17, 1996 a Streptococcus peumnoniae 0100993 DNA library in E. coli wassimilarly deposited with the NCIMB and assigned deposit number 40800.The Streptococcus pneumoniae strain deposit is referred to herein as“the deposited strain” or as “the DINA of the deposited strain.”

The deposited strain contains to full length ffh gene. The sequence ofthe polynucleotides contained in the deposited strain, as well as theamino acid sequence of the polypeptide encoded thereby, are controllingin the event of any conflict with any description of sequences herein.

The deposit of the deposited strain has been made under the terms of theBudapest Treaty on the International Recognition of the Deposit ofMicro-organisms for Purposes of Patent Procedure. The strain will beirrevocably and without restriction or condition released to the publicupon the issuance of a patent. The deposited stain is provided merely asconvenience to those of skill in the art and is not an admission that adeposit is required for enablement, such as that required under 35U.S.C. §112.

A license may be required to make, use or sell the deposited stain, andcompounds derived therefrom, and no such license is hereby granted.

Polypeptides

The polypeptides of the invention include the polypeptide of Table. 1[SEQ ID NO:2](in particular the mature polypeptide) as well aspolypeptides at fragments, particularly those which have the biologicalactivity of ffh, and also those which have at least 90% identity to thepolypeptide of Table 1 (SEQ ID NO:2π or A relevant portion, preferablyat least 95% identity to the polypeptide of Table 1 [SEQ ID NO:2], andmore preferably at 95% similarity (more preferably at least 97.5%identity) to the polypeptide of Table 1 [SEQ ID NO:2] and still morepreferably at least 97.51% similarity (still mot preferably at least 99%identity) to the polypeptide of Table 1 [SEQ ID NO:2] and also includeportions of such polypeptides with such portion of the polypeptidegenerally containing a least 30 amino acids and more preferably at least50 amino acids.

The invention also includes polypeptides of the formula set forth inTable 1 (D) wherein, at the amino terminus, X is hydrogen, and at thecarboxyl terminus, Y is hydrogen or a metal, R₁ and R₂ is any amino acidresidue, and n is an integer between 1 and 1000. Any stretch of aminoacid residues denoted by either R group, where R is greater than 1, maybe either a heteropolymer or a homopolymer, preferably a heteropolymer.

A fragment is a variant polypeptide having an amino acid sequence thatentirely is the same as part but not all of the amino acid sequence ofthe aforementioned polypeptides. As with ffh polypeptides fragments maybe “free-standing,” or comprised within a larger polypeptide of whichthey form a part or region, most preferably as a single continuousregion, a single larger polypeptide.

Preferred fragments include, for example, truncation polypeptides havinga portion of the amino acid sequence of Table 1 [SEQ ID NO:2], or ofvariants thereof such as a continuous series of residues that includesthe amino terminus, or a continuous series of residues that includes thecarboxyl terminus. Degradation forms of the polypeptides of theinvention in a host cell, particularly a Streptococcus pneumoniae, arealso preferred. Further preferred are fragments characterized bystructural or functional attributes such as fragments that comprisealpha-helix and alpha-helix forming regions, beta-sheet andbeta-sheet-forming regions, turn and turn-forming regions, coil andcoil-forming regions, hydrophilic regions, hydrophobic regions, alphaamphipathic regions, beta amphipathic regions, flexible regions,surface-forming regions, substrate binding region, and high antigenicindex regions.

Also preferred are biologically active fragments which are thosefragments that mediate activities of ffh, including those with a similaractivity or an improved activity, or with a decreased undesirableactivity. Also included are those fragments that are antigenic orimmunogenic in an animal, especially in a human. Particularly preferredare fragments comprising receptors or domains of enzymes that confer afunction essential for viability of Streptococcus pneumoniae or theability to initiate, or maintain cause disease in an individual,particularly a human.

Variants that are fragments of the polypeptides of the invention may beemployed for producing the corresponding full-length polypeptide bypeptide synthesis; therefore, these variants may be employed asintermediates for producing the full-length polypeptides of theinvention.

Polynucleotides

Another aspect of the invention relates to isolated polynucleotides thatencode the ffh polypeptide having the deduced amino acid sequence ofTable 1 [SEQ ID NO:2] and polynucleotides closely related thereto andvariants thereof.

Using the information provided herein, such as the polynucleotidesequence set out in Table 1 [SEQ ID NO: 1 ], a polynucleotide of theinvention encoding ffh polypeptide may be obtained using standardcloning and screening methods, such as those for cloning and sequencingchromosomal DNA fragments from bacteria using Streptococcus pneumoniae0100993 cells as starting material, followed by obtaining a full lengthclone. For example, to obtain a polynucleotide sequence of theinvention, such as the sequence given in. Table 1 [SEQ ID NO:1],typically a library of clones of chromosomal DNA of Streptococcuspneumoniae 0100993 in E. coli or same other suitable host is probed witha radiolabeled oligonucleotide, preferably a 17-mer or longer, derivedfrom a partial sequence. Clones carrying DNA identical to that of theprobe can then be distinguished using stringent conditions. Bysequencing the individual clones thus identified with sequencing primersdesigned from the original sequence it is then possible to clad thesequence in both directions to determine the full gene sequence.Conveniently, such sequencing is performed using denatured doublestranded DNA prepared from a plasmid clone. Suitable techniques aredescribed by Maniatis, T., Fritsch, E. F. and Sambrook et al., MOLECULARCLONING, A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor LaboratoryPress, Cold Spring Harbor, N.Y. (1989). (see in particular Screening ByHybridization 1.90 and Sequencing Denatured Double-Stranded DNATemplates 13.70). Illustrative of the invention, the polynucleotide setout in Table 1 [SEQ ID NO:1] was discovered in a DNA library derivedfrom Streptococcus pneumoniae 0100993.

The DNA sequence set out in Table 1 [SEQ ID NO:1] contains an openreading frame encoding a protein having about the number of amino acidresidues set forth in Table 1 [SEQ ID NO:2] with a deduced molecularweight that can be calculated using amino acid residue molecular weightvalues ffh, known in the art. The polynucleotide of SEQ ID NO: 1,between nucleotide number 1 through number 1569 encodes the polypeptideof SEQ ID NO:2. The stop codon begins at nucleotide number 1570 of SEQID NO: 1.

The ffh protein of the invention is structurally related to otherproteins of the ffh (Fifty-Four Homologue) family, as shown by theresults of sequencing the DNA encoding ffh of the deposited strain. Theprotein exhibits greatest homology to ffh, encoded by Streptococcusmutans nucleotides 969 to 2519 of Genbank Entry Accession number U88582protein among known proteins. The ffh protein of Table 1 [SEQ ID NO:2]has about 86% identity over its entire length and about 92% similarityover its entire length with the amino acid sequence of ffh polypeptideencoded by Streptococcus mutans.

The invention provides a polynucleotide sequence identical over itsentire length to the coding sequence in Table 1 [SEQ ID NO:1]. Alsoprovided by the invention is the coding sequence for the maturepolypeptide or a fragment thereof, by itself as well as the codingsequence for the mature polypeptide or a fragment in reading frame withother coding sequence such as those encoding a leader or secretorysequence, a pre-, or pro- or prepro-protein sequence. The polynucleotidemay also contain non-coding sequences; including for example, but notlimited to non-coding 5′ and 3′ sequences, such as the transcribed,non-translated sequences, termination signals, ribosome binding sites,sequences that stabilize mRNA, introns, polyadenylation signals, andadditional coding sequence which encode additional amino acids. Forexample, a marker sequence that facilitates purification of the fusedpolypeptide can be encoded. In certain embodiments of the invention, themarker sequence is a hexa-histidine peptide, as provided in the pQEvector (Qiagen, Inc.) and described in Gentz et al., Proc. Natl. Acad.Sci., USA 86: 821-824 (1989), or an HA tag (Wilson et al., Cell 37: 767(1984). Polynucleotides of the invention also include, but are rotlimited to, polynucleotides comprising a structural gene and itsnaturally associated sequences that control gene expression.

A preferred embodiment of the invention is the polynucleotide comprisingnucleotide 1 to 1569 set forth in SEQ ID NO:1 of Table 1 which encodesthe ffh polypeptide.

The invention also includes polynucleotides of the formula set forth inTable 1 (C) wherein, at the 5′ end of the molecule, X is hydrogen, andat the 3′ end of the molecule, Y is hydrogen or a metal, R₁ and R₂ isany nucleic acid residue, and n is an integer between 1 and 1000. Anystretch of nucleic acid residues denoted by either R group, where R isgreater than 1, any be either a heteropolymer or a homopolymer,preferably a heteropolymer.

The term “polynucleotide encoding a polypeptide” as used hereinencompasses polynucleotides that include a sequence encoding apolypeptide of the invention, particularly a bacterial polypeptide andmore particularly a polypeptide of the Streptococcus pneumoniae ffhhaving the amino acid sequence set the in Table 1 [SEQ ID NO:2]. Theterm also encompasses polynucleotides that include a single continuousregion or discontinuous regions encoding the polypeptide (for example,interrupted by integrated phage or an insertion sequence or editing)together with additional regions, that also may contain coding and/ornon-coding sequences.

The invention further relates to variants of the polynucleotidesdescribed, herein that encode for variants of the polypeptide having thededuced amino acid sequence of Table 1 [SEQ ID NO:2]. Variants that arefragments of the polynucleotides of the invention may be used tosynthesize full-length polynucleotides of the invention.

Further particularly preferred embodiments are, polynucleotides encodingffh variants, that have the amino acid sequence of ffh polypeptide ofTable 1, [SEQ ID NO:2] in which several, a few, 5to 10, 1 to 5, 1 to 3,2, 1 or no amino acid residues are substituted, deleted or added, in anycombination. Especially preferred among too at Kent substitution,additions and deletions, that do not alter the properties and activitiesof ffh.

Further preferred embodiments of the invention are polynucleotides thatare at least 70% identical over their entire length to a polynucleotideencoding ffh polypeptide having the amino acid sequence set out in Table1 [SEQ ED NO:2], and polynucleotides that are complementary to suchpolynucleotides. Alternatively, most highly preferred ffhpolynucleotides that comprise a region that is at least 80% identicalover its entire length to a polynucleotide encoding ffh polypeptide ofthe deposited strain and polynucleotides complementary thereto. In thisregard, polynucleotides at least 90% identical over their entire lengthto the same are particularly preferred, and among these particularlypreferred polynucleotides, those with at least 95% are especiallypreferred. Furthermore, those with at least 97% are highly preferredamong those with at least 95%, and among these those with at least 98%and at least 99% are particularly highly preferred, with at least 99%being do more preferred.

Preferred embodiments are polynucleotides that encode polypeptides thatremain substantially the same biological function or activity as themature polypeptide encoded by the DNA of Table 1 [SEQ ID NO: 1].

The invention further relates to polynucleotides that hybridize to theherein above-described sequences. In this regard, the inventionespecially relates to polynucleotides that hybridize under stringentconditions to the herein above-described polynucleotides. As hereinused, the terms “stringent conditions” as “stringent hybridizationconditions” mean hybridization will occur only if there is at least 95%and preferably at least 97% identity between the sequences. As exampleof stringent hybridization conditions is overnight incubation at 42° C.in a solution comprising: 50% formamide, 5x SSC (150 mM NaCl, 15 mMtrisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt'ssolution, 10% dextran sulfate, and 20 micrograms/ml denatured, shearedsalmon sperm DNA, followed by washing the hybridization support in 0.1xSSC at about 65° C. Hybridization and wash conditions are well known andexemplified in Sambrook, et al., Molecular Cloning: A Laboratory Manual,Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter11 therein.

The invention also provides a polynucleotide consisting essentially of apolynucleotide sequence obtainable by screening an appropriate librarycontaining the complete gene for a polynucleotide sequence set forth inSEQ ID NO:1 under stringent hybridization conditions with a probe havingthe sequence of said polynucleotide sequence set forth in SEQ ID NO:1 ora fragment thereof, and isolating said DNA sequence. Fragments usefulfor obtaining such a polynucleotide include, for example, probes andprimers described elsewhere herein.

As discussed additionally herein regarding polynucleotide assays of theinvention, for instance, polynucleotides of the invention as discussedabove, may be used as a hybridization probe for RNA, cDNA and genomicDNA to isolate full-length cDNAs and genomic clones encoding ffh and toisolate cDNA and genomic clones of other genes that have a high sequencesimilarity to the ffh gene. Such probes generally will comprise at least15 bases. Preferably, such probes will have at least 30 bases and mayhave at least 50 bases. Particularly preferred probes will have at least30 bases and will have 50 bases or less.

For example, the coding region of the ffh gene may be isolated byscreening using the DNA sequence provided in SEQ ID NO: 1 to synthesizean oligonucleotide probe. A labeled oligonucleotide having a sequencecomplementary to that of a gene of the invention is then used to screena library of cDNA, genomic DNA or mRNA to determine which members of thelibrary the probe hybridizes to.

The polynucleotides and polypeptides of the invention may be employed,for example, as research reagents and materials for discovery oftreatments of and diagnostics for disease, particularly human disease,as further discussed herein relating to polynucleotide assays.

Polynucleotides of the invention that are oligonucleotides derived fromthe sequences of SEQ ID NOS:1 and/or 2 may be used in the processesherein as described, but preferably for PCR, to, determine whether ornot the polynucleotides identified herein in whole or in part are inbacteria in infected tissue. It is recognized that such sequences willalso have utility in diagnosis of the stage of infection and type ofinfection the pathogen has attained.

The invention also provides polynucleotides that may encode apolypeptide that is the mature protein plus additional amino orcarboxyl-terminal amino acids, or amino acids interior to the maturepolypeptide (when the mature form has more than one polypeptide chain,for instance). Such sequences may play a role in processing of a proteinfrom precursor to a mature form, may allow protein transport, maylengthen or shorten protein half-life or may facilitate manipulation ofa protein for assay or production, among other things. As generally isthe case in vivo, the additional amino acids may be processed away funthe mature protein by cellular enzymes.

A precursor protein, having the mature form of the polypeptide fused toone or more prosequences may be an inactive form of the polypeptide.When prosequences at removed such inactive precursors generally areactivated. Same or all of the prosequences may be removed beforeactivation. Generally, such precursors are called proproteins,

In sum, a polynucleotide of the invention may encode a mature protein, amature protein plus a leader sequence (which may be referred to as apreprotein), a precursor of a mature protein having one or moreprosequences that are not the leader sequences of a preprotein, or apreproprotein, which is a precursor to a proprotein, having a leadersequence and one or more prosequences, which generally are removedduring processing steps that produce active and mature forms of thepolypeptide,

Vectors, Host Cells, Expression

The invention also relates to vectors that comprise a polynucleotide orpolynucleotides of the invention, host cells that are geneticallyengineered with vectors of the invention and the production ofpolypeptides of the invention by recombinant technique. Cell-freetranslation systems can also be employed to produce such proteins usingRNAs derived from the DNA constructs of the invention.

For recombinant production, host cells can be genetically engineered toincorporate expression systems or portions thereof or polynucleotides ofthe invention. Introduction of a polynucleotide into the host cell canbe effected by methods described in many standard laboratory manuals,such as Davis et. al., BASIC METHODS IN MOLECULAR BIOLOGY, (1986) andSambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed., ColdSpring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), such atcalcium phosphate transfection, DEAE-dextran mediated transfection,transvection, microinjection, cationic lipid-mediated transfection,electroporation, transduction, scrape loading, ballistic introductionand infection.

Representative examples of appropriate hosts include bacterial cells,such as streptococci, staphylococci, enterococci E. coli, streptomycesand Bacillus subtilis cells; fungal cells, such as yeast cells andAspergillus cells; insect cells such as Drosophila S2 and Spodoptera Sf9cells; animal cells such as CHO, COS, HeLa, C 127, 3T3, BHK, 293 andBowes melanoma cells; and plant cells.

A great variety of expression systems can be used to produce thepolypeptides of the invention. Such vectors include, among others,chromosome, episomal and virus-derived vectors, e.g., vectors derivedfrom bacterial plasmids, from bacteriophage, from transposons, fromyeast episomes, from insertion elements, from yeast chromosomalelements, from viruses such as baculoviruses, papova viruses, such asSV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabiesviruses and retroviruses, and vectors derived from combinations thereof,such as those derived from plasmid and bacteriophage genetic elements,such as cosmids and phagemids. The expression system constructs maycontain control regions that regulate as well as engender expression.Generally, any system or vector suitable to maintain, propagate orexpress polynucleotides and/or to express a polypeptide in a host may beused for expression in this regard. The appropriate DNA sequence may beinserted into the expression system by any of a variety of well-knownand routine techniques, such as, for example, those set forth inSambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL, (supra).

For secretion of the translated protein into the lumen of theendoplasmic reticulum, into the periplasmic space or into theextracellular environment, appropriate secretion signals may beincorporated into the expressed polypeptide. These signals may beendogenous to the polypeptide or they may be heterologous signals.

Polypeptides of the invention can be recovered and purified fromrecombinant cell cultures by well-known methods including ammoniumsulfate or ethanol precipitation, acid extraction, anion or cationexchange chromatography, phosphocellulose chromatography, hydrophobicinteraction chromatography, affinity chromatography, hydroxylapatitechromatography, and lectin chromatography. Most preferably, highperformance liquid chromatography is employed for purification. Wellknown techniques for refolding protein may be employed to regenerateactive conformation when polypeptide is denatured during isolation andor purification.

Diagnostic Assays

This invention is also related to the use of the ffh polynucleotides ofthe invention for us as diagnostic reagents. Detection of ffh in aeukaryote, particularly a mammal, and especially a human, will provide adiagnostic method for diagnosis of a disease. Eukaryotes (herein also“individual(s)”), particularly mammals, and especially humans, infectedwith an organism comprising the ffh gene may be detected at the nucleicacid level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from an infectedindividual's cells and tissues, such as bone, blood, muscle, cartilage,and skin. Genomic DNA may be used directly for detection or may beamplified enzymatically by using PCR or other amplification techniqueprior to analysis. RNA or cDNA may also in used in the same ways. Usingamplification characterization of the species and stain of prokaryotepresent in an individual, may be made by an analysis of the genotype ofthe prokaryote gene. Deletions and insertions can be detected by achange in size of the amplified product in comparison to the genotype ofa reference sequence. Point mutations can be identified by hybridizingamplified DNA to labeled ffh polynucleotide sequences. Perfectly matchedsequences can be distinguished from mismatched duplexes by RNasedigestion or by differences in melting temperatures. DNA sequencedifferences may also be detected by alterations in the electrophoreticmobility of the DNA fragments in gels, with or without denaturingagents, or by direct DNA sequencing. See, e.g., Myers et al., Science,230: 1242 (1985). Sequence changes at specific locations also may berevealed by nuclease protection assays, such as RNase and S1 protectionor a chemical cleavage method. See, e.g., Cotton et al., Proc Natl.Acad. Sci., USA, 85: 4397-1401 (1985).

Cells carrying mutations or polymorphisms in the gene of the inventionmay also be detected at the DNA level by a variety of techniques, toallow for serotyping, for example. For example, RT-PCR can be used todetect mutations. It is particularly preferred to used RT-PCR inconjunction with automated detection systems, such as, for example,GeneScan. RNA or cDNA may also be used for the same purpose, PCR orRT-PCR. As an example, PCR primers complementary to a nucleic acidencoding ffh can be used to identify and analyze mutations.

The invention further provides these primers with 1, 2, 3 or 4nucleotides removed from the 5′ and/or the 3′ end. These primers may beused for, among other things, amplifying ffh DNA isolated from a samplederived from an individual. The primers may be used to amplify the geneisolated from an infected individual such that the gene may then besubject to various techniques elucidation of the DNA sequence. In thisway, mutations in the DNA sequence may be detected and used to diagnoseinfection and to serotype and/or classify the infectious agent.

The invention further provides a process for diagnosing, disease,preferably bacterial infections, more preferably infections byStreptococcus pneumoniae, and most preferably otitis media,conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleuralempyema, and endocarditis, and most particularly meningitis, such as forexample infection of cerebrospinal fluid, comprising determining from asample derived from an individual a increased level of expression ofpolynucleotide having the sequence of Table 1 [SEQ ID NO: 1]. Increasedor decreased expression of ffh polynucleotide can be measured using anyon of the methods well known in the art for the quantation ofpolynucleotides such as, for example, amplification, PCR, RT-PCR, RNaseprotection, Northern blotting and other hybridization methods.

In addition, a diagnostic assay in accordance with the invention fordetecting over-expression of ffh protein compared to normal controltissue samples may be used to detect the presence of an infection, forample. Assay techniques that can be used to determine levels of a ffhprotein, in a sample derived from a host are well-known to those ofskill in the art. Such assay methods include radioimmunoassays,competitive-binding assays, Western Blot analysis and ELISA assays.

Antibodies

The polypeptides of the invention or variants thereof, or cellsexpressing them can be used as an immunogen to produce antibodiesimmunospecific for such polypeptides. “Antibodies” as used hereinincludes monoclonal mA polyclonal antibodies, chimeric, single chain,simianized antibodies and humanized antibodies as well as Fab fragments,including the products of an Fab immunoglobulin expression library.

Antibodies generated against the polypeptides of the invention can beobtained by administering the polypeptides or epitope-bearing fragments,analogues or cells to an animal, preferably a nonhuman, using routineprotocols. For preparation of monoclonal antibodies, any technique knownin the art that provides antibodies produced by continuous cell linecultures can be used. Examples include various techniques, such as thosein Kohler G. and Milstein, C., Nature 256: 495-497 (1975); Kozbor etal., Immunology Today 4: 72 (1983); Cole et al., pg, 77-96 in MONOCLONALANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inv. (1985).

Techniques for the production of single chain antibodies (U.S. Pat. No.4,946,778) can be adapted to produce single chain antibodies topolypeptides of this invention. Also, transgenic mice, or otherorganisms such as other mammals, may be used to express humanizedantibodies.

Alternatively phage display technology may be utilized to selectantibody genes with binding activities towards the polypeptide eitherfrom repertoires of PCR amplified v-genes of lymphocytes from humansscreened for possessing anti-ffh or from naive libraries (McCafferty, J.et al., (1990), Nature 348, 552-554; Marks, J. et al., (1992)Biotechnology 10, 779-783). The affinity of these antibodies can also beimproved by chain shuffling (Clackson, T. et al., (1991) Nature 352,624-628).

If two antigen binding domains are present each domain may be directedagainst a different epitope-termed ‘bispecific’ antibodies.

The above-described antibodies, may be employed to isolate or toidentify clones expressing the polypeptides to purify the polypeptidesby affinity chromatography.

Thus, among others, antibodies against ffh—polypeptide may be employedto treat infections, particularly bacterial infections and especiallyotitis media, conjunctivitis, pneumonia, bacteremia, meningitissinusitis, pleural empyema and endocarditis, and most particularlymeningitis, such as for example infection of cerebrospinal fluid.

Polypeptide variants include antigenically, epitopically orimmunologically equivalent variants that form a particular aspect ofthis invention. The term “antigenically equivalent derivative” as usedherein encompasses a polypeptide or its equivalent which will bespecifically recognized by certain antibodies which, when raised to theprotein or polypeptide according to the invention, interfere with theimmediate physical interaction between pathogen and mammalian host. Theterm “immunologically equivalent derivative” as used herein encompassesa peptide or its equivalent which when used in a suitable formulation toraise antibodies in a vertebrate, the antibodies act to interfere withthe immediate physical interaction between pathogen and mammalian host.

The polypeptide, such as an antigenically or immunologically equivalentderivative or a fusion protein thereof is used as an antigen to immunizea mouse or other animal such as a rat or chicken. The fusion protein mayprovide stability to the polypeptide, The antigen may be associated, forexample by conjugation, with an immunogenic carrier protein for examplebovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH).Alternatively a multiple antigenic peptide comprising multiple copies ofthe protein or polypeptide, or an antigenically or immunologicallyequivalent polypeptide thereof may be sufficiently antigenic to improveimmunogenicity so as to obviate the use of a carrier.

Preferably, the antibody or variant thereof is modified to make it lessimmunogenic in the individual. For example, if the individual is humanthe antibody may most preferably be “humanized”; where thecomplimentarity determining region(s) of the hybridoma-derived antibodyhas been transplanted into a human monoclonal antibody, for example asdescribed in Jones, P. et al, (1986), Nature 321, 522-525 or Tempest atal., (1991) Biotechnology 9, 266-273.

The use of a polynucleotide of the invention in genetic immunizationwill preferably employ a suitable delivery method such as directinjection of plasmid DNA into muscles (Wolff at al, Hum Mol Genet 1992,1:361 Manthorpe at al, Hum. Gene Ther. 1963:4, 419), delivery of DNAcomplexed with specific protein carriers (Wu at al., J Biol Chem. 1989:264,16985), coprecipitation of DNA with calcium phosphate (Benvenisty &Reshef, PNAS USA, 1986:83,9551), encapsulation of DNA in various formsof liposomes (Kaneda at al., Science 1989:243,375), particle bombardment(Tang at al., Nature 1992, 356:152, Eisenbraun at al, DNA Cell Biol1993, 12:7991) and in vivo infection using cloned retroviral vectors(Seeger et al., PNAS USA 1984:81,5849).

Antagonists and Aagonists—Assays and Molecules

Polypeptides of the invention may also be used to assess the binding ofsmall molecule substrates and ligands in for example, cells, cell-freepreparations, chemical libraries, and natural product mixtures. Thesesubstrates and ligands may be natural substrates and ligands or may bestructural or functional mimetics. See, e.g., Coligan et al., CurrentProtocols in Immunology 1(2): Chapter 5 (1991),

The invention also provides a method of screening compounds to identifythose which enhance (agonist) or block (antagonist) the action of ffhpolypeptides or polynucleotides, particularly those compounds that arebacteriostatic and/or bacteriocidal. The method of screening may involvehigh-throughput techniques. For example, to screen for agonists orantogoists, a synthetic reaction mix, a cellular compartment, such as amembrane, cell envelope or cell wall, or a preparation of any thereof,comprising ffh polypeptide and a labeled substrate or ligand of suchpolypeptide is incubated in the absence or the presence of a candidatemolecule that may be a ffh agonist or antagonist. The ability of thecandidate molecule to agonize or antagonize the ffh polypeptide isreflected in decreased binding of the labeled ligand or decreasedproduction of product from such substrate. Molecules that bindgratuitously, i.e., without inducing the effects of ffh polypeptide aremost likely to be good antagonists. Molecules that bind well andincrease the rate of product production from substrate are agonists.Detection of the rate or level of production of product from substratemay be enhanced by using a reporter system. Reporter systems that may beuseful in this regard include but are not limited to colorimetriclabeled substrate converted into product, the reporter gene that isresponsive to changes in ffh polynucleotide or polypeptide activity, andbinding assays known in the art.

Another example of an assay for ffh antagonists is a competitive assaythat combines ffh and a potential antagonist with ffh-binding molecules,recombinant ffh binding molecules, natural substrates or ligands, orsubstrate or ligand mimetics, under appropriate conditions for acompetitive inhibition assay. The ffh protein can be labeled, such as byradioactivity or a colorimetric compound, such that be number of ffhmolecules bound to a binding molecule or converted to product can bedetermined accurately to assess the effectiveness of the potentialantagonist.

Potential antagonists include small organic molecules, peptides,polypeptides and antibodies that bind to a polynucleotide or polypeptideof the invention and thereby inhibit or extinguish its activity.Potential antagonists also may be small organic molecules, a peptide, apolypeptide such as a closely related protein or antibody that binds thesame sites on a binding molecule, such as a binding molecule, withoutinducing ffh-induced activities, thereby preventing the action of ffh byexcluding ffh from binding.

Potential antagonists include a small molecule that binds to andoccupies the binding site of the polypeptide thereby preventing bindingto cellular binding molecules, such that normal biological activity isprevented. Examples of small molecules include but are not limited tosmall organic molecules, peptides or peptide-like molecules. Otherpotential antagonists include antisense molecules (see Okano, JNeurochem. 56: 560 (1991); OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORSOF GENE EXPRESSION, CRC Press, Boca Raton, Fla. (1988), for adescription of these molecules). Preferred potential antagonists includecompounds related to and variants of ffh.

Each of the DNA sequences provided herein may be used in the discoveryand development of antibacterial compounds. The encoded protein, uponexpression, can be used as a target for the screening of antibacterialdrugs. Additionally, the DNA sequences encoding the amino terminalregions of the encoded protein or Shine-Delgarno or other translationfacilitating sequences of do respective mRNA can be used to constructantisense sequences to control the expression of do coding sequence ofinterest.

The invention also provides the use of the polypeptide, polynucleotideor inhibitor of the invention to interfere with the initial physicalinteraction between a pathogen and mammalian host responsible forsequelae of infection. In particular the molecules of the invention maybe used: in the prevention of adhesion of bacteria, in particular grampositive bacteria, to mammalian extracellular matrix proteins onin-dwelling devices or to extracellular matrix proteins in wounds; toblock ffh protein-mediated mammalian cell invasion by, for example,initiating phosphorylation of mammalian tyrosine kinases (Rosenshine etal., Infect. Immun. 60:2211 (1992); to block bacterial adhesion betweenmammalian extracellular matrix proteins and bacterial ffh proteins thatmediate tissue damage and; to block the normal progression ofpathogenesis in infections initiated other than by the implantation ofin-dwelling devices or by other surgical techniques.

The antagonists and agonists of the invention may be employed, forinstance, to inhibit and treat otitis media, conjunctivitis pneumonia,bacteremia, meningitis, sinusitis, pleural empyema and endocarditis itmost particularly meningitis, such as for example infection, ofcerebrospinal fluid.

Vaccines

Another aspect of the invention relates to a method for inducing animmunological response in an individual, particularly a mammal whichcomprises inoculating the individual with ffh, or a fragment or variantthereof, adequate to produce antibody and/or T cell immune response toprotect said individual from infection, particularly bacterial infectionand most particularly Streptococcus pneumoniae infection. Also providedare methods whereby such immunological response slows bacterialreplication. Yet another aspect of the invention relates to a method ofinducing response in an individual which comprises delivering to suchindividual a nucleic acid vector to direct expression of ffh, or afragment or a variant thereof, for expressing ffh, or a fragment or avariant thereof in vivo in order to induce an immunological response,such as, to produce antibody and/or T cell immune response, including,for example, cytokine-producing T cells or cytotoxic T cells, to protectsaid individual from disease, whether that disease is alreadyestablished within the individual or not. One way of administering thegene is by accelerating it into the desired cells as a coating onparticles or otherwise. Such nucleic acid vector may comprise DNA, RNA,a modified nucleic acid, or a DNA/RNA hybrid.

A Rather aspect of the invention relates to an immunological compositionwhich, when introduced into an individual capable or having inducedwithin it an immunological response, induces an immunological responsein such individual to a ffh or protein coded therefrom, wherein thecomposition comprises a recombinant ffh or protein coded therefromcomprising DNA which codes for and expresses an antigen of said ffh orprotein coded therefrom. The immunological response may be usedtherapeutically or prophylactically and may take the form of antibodyimmunity or cellular immunity such as that arising from CTL or CD4+ Tcells.

A ffh polypeptide or a fragment thereof may be fused with co-proteinwhich may not by itself produce antibodies, but is capable ofstabilizing the first protein and producing a fused protein which willhave immunogenic and protective properties. Thus fused recombinantprotein, preferably further comprises an antigenic co-protein, such aslipoprotein D from Hemophilus influenzae, Glutathione-S-transferase,GST) or beta-galactosidase, relatively large co-proteins whichsolubilize the protein and facilitate production and purificationthereof, Moreover, the co-protein may act as an adjuvant in the sense ofproviding a generalized stimulation of the immune system. The co-proteinmay be attached to either the amino or carboxy terminus of the firstprotein.

Provided by this invention, are compositions, particularly vaccinecompositions, and methods comprising the polypeptides or polynucleotidesof the invention and immunostimulatory DNA sequences, such as thosedescribed in Sato, Y. et al. Science 273: 352 (1996).

Also, provided by this invention are methods using the describedpolynucleotide or particular fragments thereof which have been shown toencode non-variable regions of bacterial cell surface proteins in DNAconstructs used in such genetic immunization experiments in animalmodels of infection with Streptococcus pneumoniae will be particularlyuseful for identifying protein epitopes able to provoke a prophylacticor therapeutic immune response. It is believed that this approach willallow for the subsequent preparation of monoclonal antibodies ofparticular value from the requisite organ of the animal successfullyresisting or clearing infection, for the development of prophylacticagents or therapeutic treatments of bacterial infection, particularlyStreptococcus pneumoniae infection, in mammals, particularly humans.

The polypeptide may be used as an antigen for vaccination of a host toproduce specific antibodies which protect against invasion of bacteria,for example by blocking adherence of bacteria to damaged tissue.Examples of tissue damage include wounds in skin or connective tissuecaused, e.g., by mechanical, chemical or thermal damage or byimplantation of indwelling devices, or wounds in the mucous membranes,such as the mouth, mammary glands, urethra or vagina.

The invention also includes a vaccine formulation which comprises animmunogenic recombinant protein of the invention together with asuitable carrier. Since the protein may be broken down in the stomach,it is preferably administered parenterally, including, for example,administration that is subcutaneous, intramuscular, intravenous, orintradermal. Formulations suitable for parenteral administration includeaqueous and non-aqueous sterile injection solutions which may containanti-oxidants, buffers, bacteriostats and solutes which render theformulation insotonic with the bodily fluid, preferably the blood, ofthe individual; and aqueous and non-aqueous sterile suspensions whichmay include suspending agents or thickening agents. The formulations maybe presented in unit-dose or multi-dose containers, for example, sealedampules and vials and may be stored in a freeze-dried conditionrequiring only the addition of the sterile liquid carrier immediatelyprior to use. The vaccine formulation may also include adjuvant systemsfor enhancing the immunogenicity of the formulation, such as oil-inwater systems and other systems known in the art. The dosage will dependon the specific activity of the vaccine and can be readily determined byroutine experimentation.

While the invention has been described with reference to certain ffhprotein, it is to be understood that this covers fragments of thenaturally occurring protein and similar proteins with additions,deletions or substations which do not substantially affect theimmunogenic properties of the recombinant protein.

Compositions, Kits and Administration

The invention also relates to compositions comprising the polynucleotideor the polypeptides discussed above or their agonists or antagonists.The polypeptides of the invention may be employed in combination with anon-sterile or sterile carrier or carriers for an with cells, tissues ororganisms, such as a pharmaceutical carrier suitable for administrationto a subject. Such compositions comprise, for instance, a media additiveor a therapeutically effective amount of a polypeptide of the inventionand a pharmaceutically acceptable carrier or excipient. Such carriersmay include but are not limited to, saline, buffered saline, dextrose,water, glycerol, ethanol and combinations thereof. The formulationshould suit the mode of administration. The invention further relates todiagnostic and pharmaceutical packs and kits comprising one or morecontainers filled with one or more of the ingredients of theaforementioned compositions of the invention.

Polypeptides aid other compounds of the invention may be employed aloneor in conjunction with other compounds, such as therapeutic compounds.

The pharmaceutical compositions may be administered in any effective,convenient manner including, for instance, administration by topical,oral, anal, vaginal, intravenous, intraperitoneal, intramuscular,subcutaneous, intranasal or intradermal routes among others.

In therapy or as a prophylactic, the active agent may be administered toan individual as an injectable composition, for example as a sterileaqueous dispersion, preferably isotonic.

Alternatively the composition may be formulated for topical applicationfor example in the form of ointments, creams, lotions, eye ointments,eye drops, ear drops, mouthwash impregnated dressings and sutures andaerosols, and may contain appropriate conventional additives, including,for example, preservatives, solvents to assist drug penetration, andemollients in ointments and creams. Such topical formulations may alsocontain compatible conventional carriers, for example cream or ointmentbases, and ethanol or oleyl alcohol for lotions, Such carriers mayconstitute from about 1% to about 98% by weight of the formulation; moreusually they will constitute up to about 80% by weight of theformulation,

For administration to mammals, and particularly humans, it is expectedthat the daily dosage level of the active agent will be from 0.01 mg/kgto 10 mg/kg, typically around 1 mg/kg. The physician in any event willdetermine the actual dosage which will be most suitable for anindividual and will vary with the age, weight and response of theparticular individual. The above dosages are exemplary of the avengecase. There can, of course, be individual instances where higher orlower dosage ranges are merited, and such are within the scope of thisinvention.

In-dwelling devices include surgical implants, prosthetic devices andcatheters, i.e., devices that are introduced to the body of anindividual and remain in position for an extended time. Such devicesinclude, for example, artificial joints, heart valves, pacemakers,vascular grafts, vascular catheters, cerebrospinal fluid shunts, urinarycatheters, continuous ambulatory peritoneal dialysis (CAPD) catheters.

The composition of the invention may be administered by injection toachieve a systemic effect against relevant bacteria shortly beforeinsertion of an in-dwelling device. Treatment may be continued aftersurgery during the in-body time of the device. In addition, thecomposition could also be used to broaden perioperative cover for anysurgical technique to prevent bacterial wound infections, especiallyStreptococcus pneumoniae wound infections.

Many orthopedic surgeons consider that humans with prosthetic jointsshould be considered for antibiotic prophylaxis before dental treatmentthat could produce a bacteremia. Late deep infection is a seriouscomplication sometimes leading to loss of the prosthetic joint and isaccompanied by significant morbidity and mortality. It may therefore bepossible to extend the use of the active agent as a replacement theprophylactic antibiotics in this situation,

In addition to the therapy described above, the compositions of thisinvention may be used generally as a wound treatment agent to preventadhesion of bacteria to matrix proteins exposed in wound tissue and forprophylactic use in dental treatment as an alternative to, or inconjunction with, antibiotic prophylaxis.

Alternatively, the composition of the invention may be used to bathe anindwelling device immediately before insertion. The active agent willpreferably be present at a concentration of 1 μg/ml to 10 mg/ml forbathing of wounds or indwelling devices.

A vaccine composition is conveniently in injectable form. Conventionaladjuvants may be employed to enhance the immune response, A suitableunit dose for vaccination is 0.5-5 microgram/kg of antigen, and suchdose is preferably administered 1-3 times and with an interval of 1-3weeks. With the indicated dose range, no adverse toxicological effectswill be observed with the compounds of the invention which wouldpreclude their administration to suitable individuals.

Each reference disclosed herein is incorporated by reference herein inits entirety. Any patent application to which this application claimspriority is also incorporated by reference herein in its entirety.

EXAMPLES

The examples below we carried a using standard techniques, which arewell known and routine to those of skill in the art except whereotherwise described in detail. The examples are illustrative, but do notlimit the invention.

Example 1 Strain Selection, Library Production and Sequencingpg,

The polynucleotide having the DNA sequence given in SEQ ID NO:1 wasobtained from a library of clones of chromosomal DNA of Streptococcuspneumoniae in E. coli. The sequencing data from two or more clonescontaining overlapping Streptococcus pneumoniae DNAs was used toconstruct the contiguous DNA. sequence in SEQ ID NO:1. Libraries may beprepared by routine methods, for example:

Methods 1 and 2 below.

Total cellular DNA is isolated from Streptococcus pneumoniae 0100993according to standard procedures and size-fractionated by either of twomethods.

Method 1

Total cellular DNA is mechanically sheared by passage through a needlein order to size-fractionate according to standard procedures. DNAfragments of up to 11 kbp in size are rendered blunt by treatment withexonuclease and DNA polymerase, and EcoRI linkers added. Fragments areligated into the vector Lambda ZapII that has been cut with EcoRI, thelibrary packaged by standard procedures and E. coli infected with thepackaged library. The library is amplified by standard procedures.

Method 2

Total cellular DNA is partially hydrolyzed with a one or a combinationof restriction enzymes appropriate to generate a series of fragments forcloning into library vectors (e.g., RsaI, PalI, AluI, Bshl235I), andsuch fragments are size-fractionated according to standard procedures.EcoRI linkers are ligated to the DNA and the fragments then ligated intothe vector Lambda ZapII that have been cut with EcoRI, the librarypackaged by standard procedures, and E. coli infected with the packagedlibrary. The library is amplified by standard procedures.

2 1569 base pairs nucleic acid double linear 1 ATGGCATTTG AAAGTTTAACAGAACGTTTG CAGAACGTCT TTAAAAATCT ACGTAAAAAA 60 GGAAAAATCT CTGAATCTGATGTCCAAGAG GCAACCAAAG AAATTCGCTT GGCCTTGCTC 120 GAGGCCGACG TTGCCTTGCCTGTTGTAAAG GACTTTATCA AGAAAGTTCG TGAGCGTGCA 180 GTCGGGCATG AGGTCATTGATACACTTAAT CCTGCGCAAC AGATTATTAA AATCGTTGAT 240 GAGGAACTGA CAGCCGTTTTAGGTTCTGAT ACGGCAGAAA TTATCAAGTC ACCTAAGATT 300 CCAACCATCA TCATGATGGTTGGTTTACAA GGGGCTGGTA AAACAACCTT TGCTGGTAAA 360 TTGGCCAACA AACTCAAGAAAGAAGAAAAT GCTCGTCCTT TGATGATTGC GGCGGATATT 420 TATCGTCCAG CTGCCATTGACCAGCTTAAG ACCTTGGGAC AACAGATTGA TGTGCCTGTC 480 TTTGCACTTG GAACAGAAGTACCAGCTGTT GAGATTGTAC GTCAAGGTTT GGAGCAAGCC 540 CAAACTAATC ATAACGACTATGTCTTGATT GATACTGCGG GTCGTTTGCA GATTGATGAG 600 CTCCTCATGA ATGAGCTTCGTGATGTGAAA GTATTGGCTC AACCAAATGA AATCTTGCTT 660 GTCGTTGATG CTATGATTGGTCAGGAAGCA GCCAATGTTG CGCGTGAGTT TAATGCTCAC 720 TTGGAAGTGA CTGGGGTCATCCTTACCAAG ATTGATGGTG ATACTCGTGG TGGTGCTGCT 780 CTGTCTGTTC GTCACATCACTGGAAAACCA ATCAAGTTCA CTGGTACAGG TGAAAAAATT 840 ACAGATATCG AAACCTTCCACCCAGACCGT ATGTCTAGCC GTATCCTTGG CATGGGGGAT 900 ATGCTCACTT TGATTGAGAAAGCTTCTCAG GAATACGATG AACAAAAAGC CCTTGAAATG 960 GCTGAGAAGA TGCGCGAAAACACCTTTGAT TTTAATGATT TCATCGATCA ATTAGATCAG 1020 GTGCAAAATA TGGGGCCGATGGAAGACTTG CTCAAGATGA TTCCAGGTAT GGCCAACAAT 1080 CCAGCACTTC AAAACATGAAGGTGGATGAA CGCCAGATTG CTCGTAAACG TGCCATTGTG 1140 TCTTCGATGA CATCTGAAGAACGTGAAAAC CCAGATTTGT TAAATCCAAG CCGTCGCCGT 1200 CGTATTGCTG CTGGTTCTGGAAATACATTC GTCGAAGTCA ATAAATTCAT CAAGGACTTT 1260 AACCAGGCTA AACAGCTCATGCAGGGTGTT ATGTCTGGGG ATATGAATAA AATGATGAAG 1320 CAAATGGGGA TTAATCCAAATAACCTTCCT AAAAATATGC CAAATATGGG AGGAATGGAT 1380 ATGTCTGCCC TTGAAGGAATGATGGGACAA GGCGGTATGC CTGACTTATC AGCTCTCGGA 1440 GGAGCAGGAA TGCCAGATATGAGCCAGATG TTTGGTGGCG GTTTGAAAGG TAAAATTGGT 1500 GAATTTGCCA TGAAACAGTCCATGAAACGT ATGGCTAACA AAATGAAGAA AGCGAAGAAG 1560 AAACGCAAG 1569 523amino acids amino acid single linear 2 Met Ala Phe Glu Ser Leu Thr GluArg Leu Gln Asn Val Phe Lys Asn 1 5 10 15 Leu Arg Lys Lys Gly Lys IleSer Glu Ser Asp Val Gln Glu Ala Thr 20 25 30 Lys Glu Ile Arg Leu Ala LeuLeu Glu Ala Asp Val Ala Leu Pro Val 35 40 45 Val Lys Asp Phe Ile Lys LysVal Arg Glu Arg Ala Val Gly His Glu 50 55 60 Val Ile Asp Thr Leu Asn ProAla Gln Gln Ile Ile Lys Ile Val Asp 65 70 75 80 Glu Glu Leu Thr Ala ValLeu Gly Ser Asp Thr Ala Glu Ile Ile Lys 85 90 95 Ser Pro Lys Ile Pro ThrIle Ile Met Met Val Gly Leu Gln Gly Ala 100 105 110 Gly Lys Thr Thr PheAla Gly Lys Leu Ala Asn Lys Leu Lys Lys Glu 115 120 125 Glu Asn Ala ArgPro Leu Met Ile Ala Ala Asp Ile Tyr Arg Pro Ala 130 135 140 Ala Ile AspGln Leu Lys Thr Leu Gly Gln Gln Ile Asp Val Pro Val 145 150 155 160 PheAla Leu Gly Thr Glu Val Pro Ala Val Glu Ile Val Arg Gln Gly 165 170 175Leu Glu Gln Ala Gln Thr Asn His Asn Asp Tyr Val Leu Ile Asp Thr 180 185190 Ala Gly Arg Leu Gln Ile Asp Glu Leu Leu Met Asn Glu Leu Arg Asp 195200 205 Val Lys Val Leu Ala Gln Pro Asn Glu Ile Leu Leu Val Val Asp Ala210 215 220 Met Ile Gly Gln Glu Ala Ala Asn Val Ala Arg Glu Phe Asn AlaGln 225 230 235 240 Leu Glu Val Thr Gly Val Ile Leu Thr Lys Ile Asp GlyAsp Thr Arg 245 250 255 Gly Gly Ala Ala Leu Ser Val Arg His Ile Thr GlyLys Pro Ile Lys 260 265 270 Phe Thr Gly Thr Gly Glu Lys Ile Thr Asp IleGlu Thr Phe His Pro 275 280 285 Asp Arg Met Ser Ser Arg Ile Leu Gly MetGly Asp Met Leu Thr Leu 290 295 300 Ile Glu Lys Ala Ser Gln Glu Tyr AspGlu Gln Lys Ala Leu Glu Met 305 310 315 320 Ala Glu Lys Met Arg Glu AsnThr Phe Asp Phe Asn Asp Phe Ile Asp 325 330 335 Gln Leu Asp Gln Val GlnAsn Met Gly Pro Met Glu Asp Leu Leu Lys 340 345 350 Met Ile Pro Gly MetAla Asn Asn Pro Ala Leu Gln Asn Met Lys Val 355 360 365 Asp Glu Arg GlnIle Ala Arg Lys Arg Ala Ile Val Ser Ser Met Thr 370 375 380 Ser Glu GluArg Glu Asn Pro Asp Leu Leu Asn Pro Ser Arg Arg Arg 385 390 395 400 ArgIle Ala Ala Gly Ser Gly Asn Thr Phe Val Glu Val Asn Lys Phe 405 410 415Ile Lys Asp Phe Asn Gln Ala Lys Gln Leu Met Gln Gly Val Met Ser 420 425430 Gly Asp Met Asn Lys Met Met Lys Gln Met Gly Ile Asn Pro Asn Asn 435440 445 Leu Pro Lys Asn Met Pro Asn Met Gly Gly Met Asp Met Ser Ala Leu450 455 460 Glu Gly Met Met Gly Gln Gly Gly Met Pro Asp Leu Ser Ala LeuGly 465 470 475 480 Gly Ala Gly Met Pro Asp Met Ser Gln Met Phe Gly GlyGly Leu Lys 485 490 495 Gly Lys Ile Gly Glu Phe Ala Met Lys Gln Ser MetLys Arg Met Ala 500 505 510 Asn Lys Met Lys Lys Ala Lys Lys Lys Arg Lys515 520

What is claimed is:
 1. An isolated polypeptide comprising SEQ ID NO:2.2. A composition comprising the isolated polypeptide of claim
 1. 3. Theisolated polypeptide of claim 1, wherein the isolated polypeptidecomprises a heterologous amino acid sequence fused to SEQ ID NO:2.
 4. Acomposition comprising the isolated polypeptide of claim 3 and acarrier.
 5. The isolated polypeptide of claim 1, wherein the isolatedpolypeptide consists of SEQ ID NO:2.
 6. A composition comprising theisolated polypeptide of claim 5, and a carrier.